AZTHERAPIES
AZTherapies is an advanced clinical-stage biopharmaceutical company developing novel therapies that aim to fundamentally change neurodegenerative disease progression, extending normal cognition and function and improving quality of life in the aging population. Advancing a growing pipeline to treat patients with few therapeutic options, the Company’s lead candidate, ALZT-OP1, is built on a multi-modal approach that recognizes neuroinflammation as a root cause of serious neurodegeneration and s... eeks to stop or slow the progression of the disease. The Phase 3 COGNITE trial in early Alzheimer’s disease is fully enrolled and expected to complete in late 2020. Following the lead program, AZTherapies is advancing candidates for the treatment of post-ischemic stroke cognitive impairment, amyotrophic lateral sclerosis (ALS), and other indications. AZTherapies is a private company founded in 2011 and headquartered in Boston, Massachusetts.
AZTHERAPIES
Social Links:
Industry:
Biopharma Biotechnology Health Care Neuroscience Pharmaceutical Therapeutics
Founded:
2011-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.aztherapies.com
Total Employee:
1+
Status:
Active
Contact:
(617) 318-3411
Email Addresses:
[email protected]
Total Funding:
99.84 M USD
Technology used in webpage:
Euro SPF Microsoft Exchange Online Google Office 365 Mail Google Cloud Microsoft Azure DNS Cloudflare DNS Google Cloud Iowa
Similar Organizations
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
AptarGroup
AptarGroup is a global solution provider of a range of packaging delivery solutions primarily for the beauty, personal care, home.
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Arcutis Biotherapeutics
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing medical dermatology for unmet needs.
Biogen Idec
Biogen Idec is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
Convergint Technologies
Convergint Technologies is a service-based global integrator of Electronic Security, Fire Alarm, Life Safety, and Healthcare Technologies.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Eliem Therapeutics
Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders.
Medable
Medable is transforming clinical research and predictive medicine by creating a platform powered by patient generated data.
Wave Life Sciences
Wave Life Sciences is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling diseases
Current Advisors List
Current Employees Featured
Founder
Investors List
THE CATALYTIC IMPACT FOUNDATION (CIF)
THE CATALYTIC IMPACT FOUNDATION (CIF) investment in Venture Round - AZTherapies
IBS Capital
IBS Capital investment in Series C - AZTherapies
Wexford Capital
Wexford Capital investment in Series C - AZTherapies
Spinnaker Capital
Spinnaker Capital investment in Series C - AZTherapies
DRADS Capital
DRADS Capital investment in Series C - AZTherapies
Cosine
Cosine investment in Series C - AZTherapies
Cosine
Cosine investment in Series B - AZTherapies
IBS Capital
IBS Capital investment in Series A - AZTherapies
Key Employee Changes
| Date | New article |
|---|---|
| 2020-10-01 | AZTherapies Announces Leadership Transition, Appointing Marc de Garidel Chief Executive Officer and Member of the Board of Directors |
Official Site Inspections
http://www.aztherapies.com
- Host name: 172.46.222.35.bc.googleusercontent.com
- IP address: 35.222.46.172
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "AZTherapies"
AZTherapies - Crunchbase Company Profile & Funding
Following the lead program, AZTherapies is advancing candidates for the treatment of post-ischemic stroke cognitive impairment, amyotrophic lateral sclerosis (ALS), and other indications. AZTherapies is a private company …See details»
AZTherapies, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Nov 1, 2024 AZTherapies is a biopharmaceutical company that is currently in the advanced clinical stage of developing innovative therapies aimed at altering the progression of …See details»
AZTherapies Company Profile 2024: Valuation, Funding …
AZTherapies was founded in 2011. Where is AZTherapies headquartered? AZTherapies is headquartered in Boston, MA. What is the size of AZTherapies? AZTherapies has 12 total employees. What industry is AZTherapies in? …See details»
AZTherapies - LinkedIn
AZTherapies, Inc. is a private, late-stage clinical biopharmaceutical company developing treatments for devastating neurological conditions. We are using an innovative, multi-modal approach that ...See details»
AZTherapies - Contacts, Employees, Board Members, Advisors
Organization. AZTherapies . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 7. Number of Board …See details»
Harnessing the Power of Neuro-Immunology with …
Apr 5, 2022 AZTherapies has candidates at different stages of the pipeline, and they are: ALZT-OP1. ALZT-OP1 is a first-in-class candidate that is based on a unique multimodal approach. Combination treatment includes an oral …See details»
AZTherapies Company Profile - Office Locations, Competitors
AZTherapies is a developer of pharmaceutical drugs designed to provide treatment for multiple neurodegenerations and neuroinflammation-related CNS diseases. Its product ALZT-OP1 is a …See details»
AZTherapies - Updates, News, Events, Signals & Triggers
Organization. AZTherapies . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Growth Insight Details. Powered by AI . Edit Growth …See details»
AZTherapies Closes $26.3 Million Series C Preferred Equity
BOSTON, Oct. 17, 2019 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend brain health, today announced the closing of a …See details»
AZTherapies Doses First Patient in Phase 2a Study of ALZT-OP1a in ...
BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the …See details»
AZTherapies Announces Leadership Transition, Appointing Marc …
Oct 1, 2020 AZTherapies is an advanced clinical-stage biopharmaceutical company developing novel small molecules and biologic therapies that aim to fundamentally change …See details»
Ex-Ipsen boss de Garidel takes the helm at AZTherapies
Oct 1, 2020 De Garidel takes over from founding CEO David Elmaleh, Ph.D., who stays on as executive chairman of the board and becomes the company’s chief scientific officer. He arrives …See details»
AZTherapies Completes COGNITE Phase 3 Alzheimer’s Clinical
Nov 18, 2020 AZTherapies is an advanced clinical-stage biopharmaceutical company developing novel small molecules and biologic therapies that aim to fundamentally change …See details»
A new publication confirms AZTherapies's innovative drug …
Jan 31, 2018 The ongoing AZTherapies Phase 3 COGNITE trial (n=600) has screened over 900 patients with over 300 randomized, 128 at week 48, and 56 at week 72, study completion. ( …See details»
AZTherapies Completes COGNITE Phase 3 Alzheimer’s Clinical …
Nov 18, 2020 Last Patient/Last Visit completed on November 13th enabling full clinical database lock BOSTON, Nov. 18, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a …See details»
AZTherapies completes its COGNITE Phase III trial for early AD
On 18 November, AZTherapies, a clinical-stage biopharmaceutical company developing novel therapies to change neurodegenerative diseases progression, announced the completion of its …See details»
AZTherapies Doses First Patient in Phase 2a Study of ALZT-OP1a in ...
Sep 9, 2020 Randomized, open-label, multi-center, dose optimization study expected to evaluate 80 patients with mild- to moderate-stage ALSBOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) …See details»
AZTherapies Announces Closing of $33.6 Million Series C-1
BOSTON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the …See details»
AZTherapies Doses First Patient in Phase 2a Study of
Sep 9, 2020 AZTherapies is an advanced clinical-stage biopharmaceutical company developing novel small molecules and biologic therapies that aim to fundamentally change …See details»
Last Patient Finishes Alzheimer's Trial Testing AZTherapies’ ALZT …
Dec 7, 2020 At study entry, the patients’ disease stage was assessed with the Clinical Dementia Rating scale — a validated measure of dementia severity. That scale also was used to rate the …See details»